Age-related macular degeneration blurs and then erodes the central detail vision you use for reading and faces, while the side vision you use to move around usually stays, so it does not take all your sight. There are two forms. The dry form is common and slow. The wet form is less common, faster, and the one that needs urgent treatment.
The strongest thing within your control is not smoking, which changes the risk of advanced disease more than anything else you can do. For people who already have intermediate disease, the AREDS2 formula slows the slide toward advanced disease by about a quarter, though it does not prevent early disease or restore lost sight. For the wet form, anti-VEGF injections started promptly preserve vision for most people who get them.
Practice Ranking
Every practice we track for Age-Related Macular Degeneration, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
4 practices · 3 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Quitting Smoking The leading modifiable risk factor for AMD. | Strong | Pro | Free to $$ | Hard | Days to Longer | |
| 2 | The Mediterranean Diet Closest Mediterranean-diet adherence tracked with far less advanced AMD; the most empowering everyday lever, on observational evidence. | Moderate | Self-Directed | $ to $$ | Moderate | Months to Longer | |
| 3 | Whole Foods Leafy greens and other carotenoid-rich vegetables tracked with less advanced AMD, feeding the same pigments the eye concentrates in the macula. | Moderate | Self-Directed | $ to $$ | Moderate to Hard | Weeks to Months | |
| 4 | Omega-3 & Fish Oil Despite the theory, adding omega-3 to the eye formula did not slow progression to advanced AMD, so do not rely on fish oil here. | Strong | Supplement | $ to $$ | Easy | Weeks to Months | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Age-related macular degeneration damages the macula, the small central part of the retina that carries fine detail. That is why it takes reading, faces, and the middle of a scene first, while the side vision you use to get around is usually kept. Even at its most advanced it leaves that peripheral sight, so it does not cause total blindness, though losing the center is disabling on its own.
There are two forms, and they behave differently. Dry (atrophic) macular degeneration is the common, slow kind: yellow deposits called drusen build up under the central retina and the light-sensing cells gradually thin. Most people at the early stage keep good vision for years, and many never progress. Its advanced stage is geographic atrophy, patches where the central retinal cells have died, leaving blind spots that slowly enlarge over years.
Wet (neovascular) macular degeneration is less common but far faster. Fragile new blood vessels grow under the retina and leak fluid or blood, so straight lines start to look wavy and a blur or dark spot can appear in the center over days to weeks. The wet form causes most of the severe sight loss from this condition, and it is the one that both needs urgent treatment and now has an effective one. The dry form can turn wet at any stage, which is why a sudden change in central vision is the signal to be seen quickly.
What Helps
Most of what protects the macula is not a supplement. The levers run from the ones you hold yourself to the treatments only a specialist can give. The graded evidence for each is in the ladder below; the order here explains why one lever ranks above another and who each one is for.
Not smoking is the strongest lever, because it changes the risk of advanced disease more than any food or supplement, and the risk falls back over the years after quitting. Diet is next and points the same way: the people who keep closest to a Mediterranean-style plate, and who eat the most leafy greens, develop less advanced disease. Spinach and collard greens carry the most weight within that pattern, because they are the food source of lutein and zeaxanthin, the two pigments that concentrate in the macula.
The AREDS2 supplement helps a narrower group than most people expect. It is for those who already have intermediate disease, or advanced disease in one eye; it slows the progression to advanced disease, does nothing for healthy eyes or early changes, and cannot bring back sight already lost. Choose the AREDS2 version made with lutein and zeaxanthin, especially with any smoking history: the original used beta-carotene, which raised lung cancer risk in people who smoke or used to.
Anti-VEGF injections changed the outlook for the wet form. A specialist injects them into the eye to block VEGF, the growth signal that drives the leaky vessels, and they hold on to vision for most people who start treatment early. That early start is what makes a sudden change in central vision a same-day matter.
A sudden change in central vision, straight lines turning wavy or a new blur or dark spot in the middle of one eye, can mean the dry form has turned wet, and anti-VEGF injections save the most sight when they start within days.
For the advanced dry form, geographic atrophy, a newer class of complement-inhibitor injections slows the growth of the atrophic patch on retinal scans, so far without a matching improvement in vision. Home monitoring ties the daily habit to all of this: checking each eye in turn against a printed Amsler grid is how a new wet change is caught, and it helps only when a new distortion sends you to be seen quickly.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Vision
The antioxidant and zinc formula cut progression to advanced AMD by about 25% in intermediate disease
For people who already have moderate macular degeneration, a specific daily antioxidant and zinc supplement lowered the chance of it getting worse by about a quarter over six years, but it did nothing for people with healthy eyes or very early changes, and it cannot bring back lost sight.
In participants with intermediate AMD, or advanced AMD in one eye, a daily formula of vitamin C, vitamin E, beta-carotene and zinc (with copper) reduced the odds of progressing to advanced AMD by about 25% (odds ratio 0.72) and the risk of moderate vision loss by about 19% over a median 6.3 years. Participants with no AMD or only early AMD showed no benefit. Measured in: 3,640 people aged 55 to 80 with a range of AMD severity, randomized to antioxidants plus zinc, antioxidants alone, zinc alone, or placebo. The benefit was confined to those who already had intermediate AMD or advanced AMD in one eye; the formula did not slow anything in people with no AMD or early AMD, and it does not restore vision already lost. This original formula contained beta-carotene, later removed for the reasons in the safety claim.
Who this may not transfer to:Both sexes were enrolled across all AMD severity categories.
The study · 1
Age-Related Eye Disease Study Research Group, high-dose vitamins C and E, beta carotene and zinc for AMD and vision loss: AREDS report no. 8 · Arch Ophthalmol 2001;119(10):1417-36
Adding omega-3 to the formula did not slow progression to advanced AMD
Adding fish-oil (omega-3) to the eye supplement made no difference to whether macular degeneration got worse in the large AREDS2 trial.
Adding omega-3 fatty acids (350 mg DHA plus 650 mg EPA daily) to the AREDS formula produced no significant reduction in progression to advanced AMD compared with the formula without them (hazard ratio 0.97, not significant) over a median five years. Measured in: 4,203 people aged 50 to 85 at high risk of advanced AMD, in a factorial randomized trial. This was the isolated supplement measured against a hard clinical endpoint; oily fish eaten as food still fits the dietary pattern linked to lower risk, which is a separate line of evidence. The trial tested one dose and formulation of DHA and EPA.
Who this may not transfer to:Both sexes were enrolled; the null result applied across the trial population.
The study · 1
Age-Related Eye Disease Study 2 (AREDS2) Research Group, lutein + zeaxanthin and omega-3 fatty acids for AMD: the AREDS2 randomized clinical trial · JAMA 2013;309(19):2005-15
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Anti-VEGF injections kept vision in about 95% with wet AMD, against 62% on sham
For the wet form of macular degeneration, regular injections that block a growth signal called VEGF preserved vision in about 95% of people and let roughly a third regain some sight, provided treatment starts promptly.
In MARINA, monthly ranibizumab kept vision (fewer than 15 letters lost) in about 95% of people with neovascular AMD at one year against 62% on sham, and about 34% gained 15 or more letters against 5% on sham. In ANCHOR, ranibizumab maintained vision in about 94 to 96% against 64% on photodynamic therapy, with mean vision improving on treatment. Measured in: 716 people in MARINA (minimally classic or occult lesions) and 423 in ANCHOR (predominantly classic lesions), both randomized trials. The benefit depends on prompt and continued treatment, and the trial regimen was monthly injection; the injections carry a small risk of intraocular infection and are given by a specialist. They treat the wet form, not the dry.
Who this may not transfer to:Both trials enrolled men and women aged 50 and older with neovascular AMD.
The studies · 2
Rosenfeld PJ et al., ranibizumab for neovascular age-related macular degeneration (MARINA) · N Engl J Med 2006;355(14):1419-31
Brown DM et al., ranibizumab versus verteporfin for neovascular age-related macular degeneration (ANCHOR) · N Engl J Med 2006;355(14):1432-44
Bevacizumab matched ranibizumab for wet-AMD vision at a fraction of the cost
The far cheaper drug bevacizumab worked about as well as the pricier ranibizumab for saving vision in wet macular degeneration.
At one year, the much cheaper bevacizumab was non-inferior to ranibizumab for visual acuity in neovascular AMD, with mean gains of 8.0 versus 8.5 letters (difference within the pre-specified equivalence margin). Rates of death, heart attack and stroke were similar between the drugs, though overall serious systemic adverse events (mostly hospitalizations) were somewhat more frequent with bevacizumab (24.1% vs 19.0%; risk ratio 1.29, 95% CI 1.01 to 1.66), a difference later analyzes did not consistently confirm. Measured in: 1,208 people with neovascular AMD randomized to bevacizumab or ranibizumab, monthly or as-needed (CATT). The two drugs were equivalent for vision, which matters because bevacizumab costs a fraction of ranibizumab; the trial did note a small difference in some non-ocular serious events that later analyzes did not consistently confirm.
Who this may not transfer to:Both sexes were enrolled; results applied across the trial population.
The study · 1
Martin et al. 2011 (CATT, ranibizumab vs bevacizumab for neovascular AMD) · N Engl J Med 2011;364(20):1897-908
Lutein and zeaxanthin cut progression about 18% more than beta-carotene in the formula
Swapping beta-carotene for two natural eye pigments, lutein and zeaxanthin, worked at least as well at slowing macular degeneration and helped most in people who ate little of them, which is why the newer formula uses them.
In the direct comparison, replacing beta-carotene with lutein (10 mg) plus zeaxanthin (2 mg) was associated with an about 18% further reduction in progression to advanced AMD (hazard ratio 0.82, 95% CI 0.69 to 0.96), and the benefit was largest in participants whose dietary intake of these pigments was lowest. Measured in: Subgroup and secondary analyzes within the 4,203-participant AREDS2 trial. The overall primary comparison of adding lutein and zeaxanthin to the formula was not statistically significant; the 18% figure comes from the pre-specified secondary analysis directly substituting the pigments for beta-carotene, so it is supporting rather than confirmatory evidence.
Who this may not transfer to:Both sexes were enrolled in AREDS2; the substitution analysis drew on the full trial.
The studies · 2
Chew et al. 2014 (AREDS2 report no. 3, secondary analyzes of lutein/zeaxanthin) · JAMA Ophthalmol 2014;132(2):142-9
Age-Related Eye Disease Study 2 (AREDS2) Research Group, lutein + zeaxanthin and omega-3 fatty acids for AMD: the AREDS2 randomized clinical trial · JAMA 2013;309(19):2005-15
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Current smokers carry about two to three times the risk of advanced AMD
Smoking is the biggest thing within your control that raises the risk of serious macular degeneration, roughly two to three times, and quitting brings the risk back down over time.
Pooling the observational evidence, current smoking was the most consistent modifiable risk factor for late AMD, with current smokers carrying roughly two to three times the risk of never-smokers, a clear dose-response with pack-years, and risk declining toward that of non-smokers over years after quitting. Measured in: Systematic reviews and meta-analyzes of population cohort and case-control studies of AMD risk factors. The underlying studies are observational, so residual confounding cannot be excluded, but the size, consistency and dose-response of the smoking association make it the strongest modifiable risk factor identified. The reviews report late AMD overall rather than separating dry and wet cleanly.
Who this may not transfer to:The pooled cohorts and case-control studies included both sexes.
The studies · 2
Chakravarthy U et al., clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis · BMC Ophthalmol 2010;10:31
Thornton J et al., smoking and age-related macular degeneration: a review of association · Eye (Lond) 2005;19(9):935-44
Closest Mediterranean-diet adherence tracked with about 40% less advanced AMD
People who ate closest to a Mediterranean diet, more vegetables, fruit, fish, nuts and olive oil, were about 40% less likely to develop the advanced form of macular degeneration.
Pooling two long population cohorts, people in the highest tier of adherence to a Mediterranean diet had about 40% lower risk of developing incident advanced AMD than those in the lowest (hazard ratio around 0.59), with the association holding after adjustment for known risk factors. Measured in: 4,996 people in the Rotterdam Study (RS-I) and the Alienor Study, followed for incident advanced AMD (EYE-RISK Consortium). What could explain it instead: Healthy-user bias: people who eat closest to a Mediterranean pattern also tend to be less likely to smoke, more active and of higher socioeconomic status, all of which independently affect AMD risk. The analysis adjusted for measured factors but cannot remove unmeasured ones.. The association was with advanced AMD specifically, and the effect for early AMD was weaker. It is dietary-pattern evidence rather than a trial, so it shows a consistent link rather than proof that changing the diet changes the outcome.
Who this may not transfer to:Both cohorts enrolled men and women aged 55 and older.
The study · 1
Merle BMJ et al., Mediterranean diet and incidence of advanced age-related macular degeneration: the EYE-RISK Consortium · Ophthalmology 2019;126(3):381-90
The most carotenoid-rich vegetables tracked with about 43% less advanced AMD
People who ate the most carotenoid-rich vegetables, especially leafy greens like spinach, had roughly 40% to 50% lower risk of advanced macular degeneration.
People in the highest fifth of carotenoid intake had about 43% lower risk of advanced AMD than those in the lowest (odds ratio 0.57). Spinach and collard greens, rich in lutein and zeaxanthin, showed the strongest individual association, with the highest intake linked to roughly half the risk. Measured in: 356 people with advanced AMD and 520 controls in the multicenter Eye Disease Case-Control Study. What could explain it instead: Recall bias and healthy-diet clustering: people eating more leafy greens differ in other health behaviors, and diet was reported after diagnosis, which can color recall.. As a case-control study asking people what they ate, it is open to recall bias and cannot establish cause, but it is the classic finding that first pointed at the macular pigments and it agrees with the later dietary-pattern evidence.
Who this may not transfer to:Both sexes were included among cases and controls.
The study · 1
Seddon JM et al., dietary carotenoids, vitamins A, C, and E, and advanced AMD (Eye Disease Case-Control Study Group) · JAMA 1994;272(18):1413-20
Pegcetacoplan slowed geographic atrophy on scans by about a fifth, with no vision benefit at two years
A newer injected drug, pegcetacoplan, slowed how fast the dead patch in advanced dry macular degeneration grew on scans by about a fifth, but it did not improve or protect sight in the trials and slightly raised the chance of the wet form.
OAKS and DERBY were two multicenter, double-masked, sham-controlled phase 3 trials enrolling 1,258 people aged 60 and older with geographic atrophy from AMD, randomized to intravitreal pegcetacoplan monthly, every other month, or sham. At 24 months, monthly pegcetacoplan slowed growth of the atrophy lesion on fundus autofluorescence by 22% in OAKS (least-squares mean difference -0.90 mm2, 95% CI -1.30 to -0.50) and 19% in DERBY (-0.75 mm2, -1.15 to -0.34), with the every-other-month arm close behind. The key secondary visual-function endpoints, including best-corrected visual acuity and functional reading, showed no difference from sham at 24 months. New-onset exudative (wet) AMD occurred in 11% to 13% of the monthly-injection eyes against 2% to 4% on sham. So the drug reliably slows the structural progression it was approved on, while its effect on the sight a person actually uses is not yet demonstrated.
Who this may not transfer to:Both trials enrolled men and women aged 60 and older with geographic atrophy from AMD; the effect was on the anatomical lesion, not on measured vision.
The study · 1
Heier JS et al., pegcetacoplan for geographic atrophy secondary to AMD (OAKS and DERBY): two phase 3 trials · Lancet 2023;402(10411):1434-48
How It Works
The macula is dense with two yellow pigments, lutein and zeaxanthin, drawn from the diet and concentrated there, where they absorb short-wavelength light and soak up the reactive oxygen that constant light exposure produces. Diets and formulas rich in these pigments aim to strengthen that protection, which is part of why leafy greens and the lutein and zeaxanthin formula rank where they do. The antioxidant and zinc combination targets the same oxidative and metabolic stress on the retinal cells.
The wet form runs on a different mechanism. When the retina is stressed it releases vascular endothelial growth factor (VEGF), a signal that drives new blood vessels to grow. Under the macula those new vessels are fragile and leak, which is what distorts and blurs central vision within days. Anti-VEGF drugs bind that signal so the abnormal vessels regress and the leaking settles, which is why they preserve vision when started before the fluid and bleeding have scarred the center.
What the Research Argues Against
One finding is about what does not help; the other is about cost.
Adding omega-3 fish oil (DHA and EPA) to the supplement formula did not slow progression to advanced macular degeneration in the large AREDS2 trial. Oily fish eaten as food still fits the Mediterranean-style pattern linked to lower risk, which is a separate line of evidence, but the isolated DHA and EPA supplement did not move the clinical outcome.
The second finding is about cost. When the cheaper drug bevacizumab was tested head-to-head against the far pricier ranibizumab for wet macular degeneration, the two came out equal for vision at one year. An effective treatment is therefore available at a fraction of the cost, which widens who can be treated.
Go Deeper
- The Mediterranean diet: the vegetable, fish, nuts and olive-oil pattern that tracks with less advanced macular degeneration, and how to eat it.
- Omega-3 and fish oil: why oily fish fits the diet that helps while the isolated supplement did not slow progression.
- Inflammation: the process behind the drusen and complement biology that the newer dry-AMD drugs target.
The Chinese Medicine View
The Chinese Medicine View
Chinese medicine has no term for macular degeneration; it reads the failing of central, detailed vision through the eye's classical relationships. The Liver is said to open into the eyes and its Blood to moisten and brighten them, while the Kidney stores the essence that sustains the eyes over a lifetime, so age-related dimming of sight is most often read as a depletion at that Liver and Kidney root. Read these patterns as an interpretive lens on how a person presents, not as a reading of what is happening in the retina, and not as a claim that the tradition foresaw the modern findings. Nothing in this tradition reverses established macular degeneration. Two cautions belong here plainly. The wet form, where new vessels leak under the retina, is a time-sensitive problem that calls for prompt anti-VEGF treatment, and the pattern below is not a substitute for that care. And the herbs are chosen to fit the pattern, so an eye formula that suits a dry, deficient picture can be wrong for a damp or stagnant one; 'eye health' products sold direct to the public also have a documented history of undeclared ingredients, so herbs belong with a qualified practitioner and a traceable supply.
The most common age-related picture: gradually blurring or dimming central vision, dry eyes, dizziness, tinnitus, low back and knee weakness, and vision that tires by evening. The classical direction is to nourish Liver and Kidney Yin and brighten the eyes, the pattern behind much traditional use of goji and chrysanthemum.
A heavier, foggier presentation: central blur with a sense of fullness, floaters, fatigue after eating, poor appetite, loose stools, and a pale swollen tongue with a greasy coat. The direction is to strengthen the Spleen and transform Damp so the clear Yang can rise to the eyes and the fluids stop pooling below.
Read where vision has dropped more abruptly or where there is bleeding under the retina: fixed dark spots, a dusky complexion, and a purplish tongue. The direction is to move Blood and free the collaterals, and this presentation in particular is the one that needs urgent ophthalmic assessment first.
Cautions
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Beta-carotene raised lung cancer in smokers, 2.1% against 0.9% in the eye trial
In AREDS2, lung cancer occurred in 2.1% of participants taking beta-carotene versus 0.9% not taking it, and 91% of those cancers were in former smokers. This matched the earlier CARET trial, where beta-carotene plus vitamin A raised lung cancer incidence by 28% (relative risk 1.28) and total mortality by 17% in current smokers and asbestos-exposed workers, which stopped that trial early. The excess lung cancer was concentrated in current and former smokers, not never-smokers, but it is why beta-carotene was removed from the eye formula and why the lutein and zeaxanthin version is the one to choose for anyone with a smoking history.Chew et al. 2014 (AREDS2 report no. 3, secondary analyzes of lutein/zeaxanthin)Omenn GS et al., effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease (CARET)
Supplements slow progression, they do not restore lost sight
The AREDS2 formula lowers the chance of intermediate disease progressing to advanced disease. It does nothing for people with healthy eyes or only early changes, and it cannot bring back vision the disease has already taken. Taking it earlier or in higher doses does not change that, and high-dose zinc is paired with a little copper because zinc alone taken long term can lower copper levels.
If you smoke or used to, choose the lutein and zeaxanthin formula
The reason beta-carotene was removed from the eye formula is that it raised lung cancer risk in current and former smokers. The lutein and zeaxanthin version carries no such signal and works at least as well, so with any smoking history it is the one to take, and check the label before buying an older beta-carotene product.
Do not self-treat the wet form instead of getting anti-VEGF promptly
When straight lines suddenly distort or a new blur or blind spot appears in the center of one eye, the dry form may have turned wet. Anti-VEGF injections preserve the most vision when they are started early, so waiting to see whether it settles, or reaching for supplements or herbs in place of specialist care, risks permanent loss that prompt treatment would have prevented.
Sourcing eye and slimming herbs safely
Products sold direct to the public for eye health, weight, and general wellness have a documented history of undeclared or substituted ingredients, and species substitution is a known hazard in the herb trade. Buy from regulated suppliers and qualified practitioners who test their material, rather than from unverified online sellers, and let the pattern and a trained herbalist decide the formula.
Age-related macular degeneration is slow for most people, and the levers that matter most are yours: not smoking, eating for your eyes, and getting seen quickly if the middle of your vision changes. The treatments that exist work best alongside those basics, and any decision about them belongs with the eye specialist who can see your retina.
When to See Someone
Most of protecting your sight is steady and in your own hands. A few situations are different, and one rule sits above the rest: a sudden change in central vision can mean the dry form has turned wet, and wet macular degeneration is treated best when it is caught within days. These are the signs to get seen about:
- Straight lines suddenly looking wavy or bent, a new blur or dark spot in the center of your vision, or a quick drop in vision in one eye, which can mean new wet macular degeneration and needs an urgent retina review, because anti-VEGF injections work best started early(seek urgent care)
- A new change on your Amsler grid, where lines that were straight now wave or a square goes missing, which is the home-monitoring sign to act on the same day(seek urgent care)
- Sudden painless loss of vision, a curtain or shadow moving across your sight, or a burst of new flashes and floaters, which can mean a retinal detachment or a blocked retinal vessel and is an emergency(seek urgent care)
- A plan to start a high-dose eye supplement if you smoke or used to, which is a reason to choose the lutein and zeaxanthin formula over any beta-carotene version
- A diagnosis of intermediate macular degeneration, or advanced disease in one eye, which is the stage at which the AREDS2 formula is worth discussing with your eye specialist
- Growing difficulty with reading, faces, driving, or steps, which is the point to ask about a low-vision assessment and the aids and rehabilitation that go with it
None of this is meant to alarm you. Macular degeneration is slow for most people, side vision is usually kept even when central detail fades, and the levers that matter most are yours to pull. The treatments that exist, the formula for the right stage and the injections for the wet form, work best alongside those basics, and any decision about them belongs with the eye specialist who can see your retina.
Common Questions
Does macular degeneration cause total blindness?
No. It damages the macula, the central part of the retina, so it takes the detailed vision used for reading and faces while the side vision used to move around is usually kept. Even advanced disease leaves that peripheral sight, so people do not go completely blind from it, though losing the center is disabling and worth every step that slows it.
What is the difference between dry and wet macular degeneration?
Dry (atrophic) macular degeneration is the common, slow form, where drusen build under the retina and the central cells gradually thin, ending in some people as geographic atrophy. Wet (neovascular) macular degeneration is less common and faster: new vessels grow under the retina and leak, distorting vision over days. The dry form can turn wet at any point, and the wet form is the one that needs urgent anti-VEGF treatment.
Should I take the AREDS2 supplement?
It helps a specific group: people who already have intermediate macular degeneration, or advanced disease in one eye. For them the AREDS2 formula lowered the risk of progressing to advanced disease by about a quarter over six years. It was not shown to help people with healthy eyes or only early changes, and it does not restore lost sight, so discuss it with your eye specialist once your stage is known.
Why was beta-carotene taken out of the eye formula?
Because in large trials beta-carotene raised the risk of lung cancer in people who smoke or used to smoke. The updated AREDS2 formula replaces it with lutein and zeaxanthin, two pigments concentrated in the macula, which worked at least as well and carry no such risk. Anyone with a smoking history should choose the lutein and zeaxanthin version.
Does fish oil help macular degeneration?
Adding omega-3 fish oil (DHA and EPA) to the supplement formula did not slow progression to advanced disease in the AREDS2 trial. Oily fish eaten as food still fits the Mediterranean-style pattern that tracks with lower risk, so eating oily fish and taking a fish-oil supplement are separate questions, and it is the diet that tracks with the benefit.
Is the cheaper wet-AMD injection as good as the expensive one?
For vision, yes. In a head-to-head trial, bevacizumab matched the far pricier ranibizumab for visual acuity at one year in wet macular degeneration. That is why bevacizumab is widely used, since it delivers the same visual benefit at a fraction of the cost.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 14 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.